Equities research analysts expect that Charles River Laboratories International, Inc. (NYSE:CRL) will report earnings of $1.22 per share for the current quarter, Zacks Investment Research reports. Eight analysts have made estimates for Charles River Laboratories International’s earnings, with the lowest EPS estimate coming in at $1.21 and the highest estimate coming in at $1.27. Charles River Laboratories International reported earnings of $1.20 per share during the same quarter last year, which would indicate a positive year over year growth rate of 1.7%. The business is expected to report its next quarterly earnings results before the market opens on Wednesday, August 9th.

On average, analysts expect that Charles River Laboratories International will report full year earnings of $5.10 per share for the current fiscal year, with EPS estimates ranging from $5.06 to $5.15. For the next year, analysts anticipate that the business will report earnings of $5.63 per share, with EPS estimates ranging from $5.50 to $5.81. Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover Charles River Laboratories International.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, May 10th. The medical research company reported $1.29 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.15. The firm had revenue of $445.80 million during the quarter, compared to the consensus estimate of $437.04 million. Charles River Laboratories International had a net margin of 9.28% and a return on equity of 27.46%. The firm’s revenue was up 25.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.98 earnings per share.

A number of analysts have weighed in on the company. Jefferies Group LLC reiterated a “buy” rating and issued a $106.00 price target on shares of Charles River Laboratories International in a research report on Friday, April 21st. Barclays PLC restated a “hold” rating and set a $102.00 target price on shares of Charles River Laboratories International in a report on Wednesday. Citigroup Inc. restated a “neutral” rating and set a $104.00 target price (up previously from $91.00) on shares of Charles River Laboratories International in a report on Wednesday, June 28th. Zacks Investment Research upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $111.00 target price on the stock in a report on Wednesday, July 12th. Finally, BidaskClub upgraded Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a report on Tuesday, June 20th. One analyst has rated the stock with a sell rating, four have issued a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $97.06.

Charles River Laboratories International (CRL) traded down 0.16% during trading on Wednesday, reaching $99.53. 18,029 shares of the company’s stock were exchanged. The stock’s 50-day moving average price is $97.64 and its 200-day moving average price is $89.46. The company has a market capitalization of $4.74 billion, a price-to-earnings ratio of 29.13 and a beta of 1.03. Charles River Laboratories International has a 52-week low of $67.20 and a 52-week high of $102.32.

Charles River Laboratories International declared that its board has authorized a stock repurchase plan on Wednesday, May 10th that authorizes the company to repurchase $150.00 million in outstanding shares. This repurchase authorization authorizes the medical research company to buy shares of its stock through open market purchases. Shares repurchase plans are usually a sign that the company’s management believes its stock is undervalued.

ILLEGAL ACTIVITY NOTICE: “Charles River Laboratories International, Inc. (CRL) Expected to Announce Earnings of $1.22 Per Share” was reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2017/07/19/charles-river-laboratories-international-inc-crl-expected-to-announce-earnings-of-1-22-per-share.html.

In other Charles River Laboratories International news, Chairman James C. Foster sold 43,154 shares of the stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $100.00, for a total value of $4,315,400.00. Following the transaction, the chairman now owns 361,178 shares of the company’s stock, valued at $36,117,800. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director George Massaro sold 3,830 shares of the stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $100.81, for a total value of $386,102.30. Following the completion of the transaction, the director now directly owns 18,731 shares in the company, valued at approximately $1,888,272.11. The disclosure for this sale can be found here. Insiders sold 80,499 shares of company stock worth $7,946,191 in the last three months. Insiders own 2.20% of the company’s stock.

Several large investors have recently made changes to their positions in CRL. Envestnet Asset Management Inc. increased its stake in shares of Charles River Laboratories International by 41.8% in the fourth quarter. Envestnet Asset Management Inc. now owns 1,785 shares of the medical research company’s stock valued at $135,000 after buying an additional 526 shares during the period. Wsfs Capital Management LLC acquired a new stake in shares of Charles River Laboratories International during the fourth quarter valued at about $205,000. MAI Capital Management acquired a new stake in shares of Charles River Laboratories International during the first quarter valued at about $224,000. Massmutual Trust Co. FSB ADV increased its stake in shares of Charles River Laboratories International by 5.0% in the first quarter. Massmutual Trust Co. FSB ADV now owns 2,739 shares of the medical research company’s stock valued at $246,000 after buying an additional 130 shares during the period. Finally, Opus Point Partners Management LLC acquired a new stake in shares of Charles River Laboratories International during the fourth quarter valued at about $252,000. Institutional investors own 97.61% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Get a free copy of the Zacks research report on Charles River Laboratories International (CRL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.